Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pantheon International NAV increases in July

(Sharecast News) - Private equity investor Pantheon International said on Friday that its net asset value had increased 3.7% in July to 510.4p per share, primarily by favourable foreign exchange movements and valuation gains, while total NAV grew to £2.3bn. During July, Pantheon invested £7.0m in share buybacks, bringing its year-to-date total to £19m out of a £30m allocation earmarked for the period between June and the August NAV publication, repurchasing 2.17m shares at a weighted average price of 321.1p per share - an average discount of 35.0% to the prevailing net asset value per share at the time of the transactions.

Pantheon also said it had committed £47.3m to new investments in July, including a co-investment in US-based Penta Group, a manager-led secondary transaction alongside Five Arrows, and a primary commitment to Hg Genesis 11. Net portfolio cash flow was £8.6m at the end of the month, with distributions of £23.1m exceeding capital calls of £14.5m.

The trust also said its net debt to NAV ratio stood at 9.5%, excluding its Asset Linked Note, with £105m drawn from its £400m revolving credit facility and $150m in private placement notes outstanding.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.